Companies:

 

Articles:

 
Biotech

EVE Health Group Commences Distribution of Dyspro Gummies to Treat Period Pain

Go to Imelda Cotton author's page
By Imelda Cotton - 
EVE Health ASX Distribution Dyspro Gummies Treat period pain
Copied

EVE Health Group (ASX: EVE) has commenced dispatching its proprietary women’s health product Dyspro to distribution partners in preparation for an Australian launch.

Dyspro is a first-in-class, cannabinoid-based gummy for the symptoms of dysmenorrhoea (painful menstruation) and endometriosis, two of the most prevalent and under-addressed conditions in women’s health.

Following the completion of commercial-scale production, the product is now available for prescription under established regulatory pathways, with the company expecting first patient access shortly.

TeleDocs Clinic Partnership

EVE has established a national prescribing and education partnership with TeleDocs Clinic to provide streamlined access to Dyspro through its telehealth service, supported by a network of more than 3500 Australian pharmacies.

The collaboration ensures the ability to prescribe the product via digital consultations and dispensed nationwide to EVE’s target market.

EVE is evaluating additional prescription and distribution partnerships to diversify patient access pathways and support future export opportunities.

‘A Transformational Moment’

EVE chief scientific officer Dr Stuart Gunzburg said the start of Dyspro sales would be a “monumental milestone” for the company.

“Moving Dyspro from the laboratory to large-scale manufacture and into distribution marks a transformational moment as we are now on the verge of bringing real relief to women experiencing painful and often debilitating menstrual symptoms,” he said.

“We look forward to broadening access pathways to ensure Dyspro can reach as many patients as possible.”

Highly Prevalent Condition

Dysmenorrhoea is a highly prevalent condition among Australian women of reproductive age, with 77% of women aged between 18 years and 44 years experiencing bothersome menstrual symptoms and 44% missing days of work or study.

In more severe cases, dysmenorrhoea is associated with endometriosis, which is a chronic inflammatory condition estimated to affect up to 14% of reproductive-age women.

Research has shown the average annual cost of illness per woman with chronic pelvic pain (with or without endometriosis) can be as high as US$20,898, with up to 84% of this due to lost productivity.

The global dysmenorrhoea treatment market reached US$10.9 billion in 2024 and analysts forecast it to grow at a compound annual rate of 5.73% to reach US$20 billion by 2035, with projections for the Australian endometriosis treatment market to reach US$76.4 million by 2030.